Do participants with depression receive more counseling on cardiovascular disease risk factors? The results of the WOBASZ II study
Magdalena Kozela(Jagiellonian University), Andrzej Pająk(Jagiellonian University), Krystyna Kozakiewicz(Medical University of Silesia), Witosława Misiowiec(Jagiellonian University), Tomasz Zdrojewski(Gdańsk Medical University), Agnieszka Doryńska(Institute of Cardiology), Andrzej Tykarski(Poznan University of Medical Sciences), Wojciech Drygas(Medical University of Lodz), Wojciech Bielecki(Medical University of Lodz)
Cited by 4
Related Papers
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants
|The Lancet|2024|873
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
|The Lancet|2014|713
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
|The Lancet Diabetes & Endocrinology|2016|391